fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ciprofloxacin HCL & ciprofloxacin base

1 Limited Use · 1 not a benefit

PMS-Ciprofloxacin XL · DIN 02416433 · 500 mg · extended release tablet

Limited Use, Reason for Use code 394 requiredDormant since July 31, 2026 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 394 required
Write on scriptReason for Use code 394 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 394
Reason for Use code 394 For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
PMS-Ciprofloxacin XL · DIN 02416433 Manufacturer: Pharmascience Inc.; listing date 2014-03-27 Health Canada: Dormant since 2026-07-31 · brand PMS-CIPROFLOXACIN XL · ATC J01MA02 CIPROFLOXACIN · form Tablet (immediate- and extended-release) · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Ciprofloxacin XL: Formulary list price $2.31 per unit (the source does not state the unit; exact figure $2.3110). What the ministry pays, not the patient.

Ministry pays: $2.3110 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416433)

Source record
DIN 02416433: PMS-Ciprofloxacin XL Raw flags: sec12=Y, sec3=Y Item: 084000066; group id 132; item number 0223; lccId 00161; manufacturer id PMS Source form: ER Tab; strength: 500mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3110; ministry $2.3110 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416433 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90104
Interchangeable products
Cipro XL · DIN 02247916 · not recorded
Shortage status: discontinued (December 1, 2025, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416433
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2026 — choose a marketed DIN from the same-category list.

Cipro XL · DIN 02247916 · 500 mg · extended release tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-01 — choose a marketed DIN from the same-category list.Discontinued March 1, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-03-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-03-01 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 394
Reason for Use code 394 For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Cipro XL · DIN 02247916 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2005-02-22 Health Canada: Cancelled post market since 2022-03-01 · brand CIPRO XL · ATC J01MA02 CIPROFLOXACIN · form Tablet (immediate- and extended-release) · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Bayer inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cipro XL: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247916)

Source record
DIN 02247916: Cipro XL Raw flags: notABenefit=Y, sec3=Y Item: 084000066; group id 132; item number 0223; lccId 00161; manufacturer id BAY Source form: ER Tab; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247916 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72225
Interchangeable products
PMS-Ciprofloxacin XL · DIN 02416433 · $2.3110
Shortage status: resolved shortage (ended March 1, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247916
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 1, 2022 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01MA): coverage varies; not interchangeable

  • Ciprofloxacin (Cipro): general benefit, limited Use 533, not a benefit
  • Levofloxacin (Levaquin): general benefit, not a benefit
  • Moxifloxacin (Avelox): general benefit, not a benefit
  • Norfloxacin (Noroxin): general benefit, not a benefit
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 7 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

PMS-Ciprofloxacin XL · DIN 02416433 Shortage status: discontinued (2025-12-01, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416433

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Cipro XL: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026